Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

1.

[New treatments for stroke and thromboembolism prevention in atrial fibrillation].

Shiyovich A, Khalameizer V, Katz A.

Harefuah. 2014 Jan;153(1):32-8, 64. Review. Hebrew.

PMID:
24605405
[PubMed - indexed for MEDLINE]
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
[PubMed - indexed for MEDLINE]
3.

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.

Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M.

Curr Pharm Des. 2013;19(21):3816-26. Review.

PMID:
23286429
[PubMed - indexed for MEDLINE]
4.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
[PubMed - indexed for MEDLINE]
5.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

PMID:
23391196
[PubMed - indexed for MEDLINE]
Free Article
6.

Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.

Savelieva I, Bajpai A, Camm AJ.

Ann Med. 2007;39(5):371-91.

PMID:
17701479
[PubMed - indexed for MEDLINE]
7.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
[PubMed - indexed for MEDLINE]
8.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
[PubMed - indexed for MEDLINE]
9.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
[PubMed - indexed for MEDLINE]
10.

Rivaroxaban in atrial fibrillation.

Giorgi MA, Miguel LS.

Vasc Health Risk Manag. 2012;8:525-31. doi: 10.2147/VHRM.S19825. Epub 2012 Aug 30.

PMID:
22973107
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.

Lang NN, Connelly DT.

J R Coll Physicians Edinb. 2013;43(2):151-8. doi: 10.4997/JRCPE.2013.213. Review.

PMID:
23734359
[PubMed - indexed for MEDLINE]
12.

An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.

Deedwania P, Huang GW.

Rev Cardiovasc Med. 2012;13(2-3):e89-104. Review.

PMID:
23160166
[PubMed - indexed for MEDLINE]
13.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
[PubMed - indexed for MEDLINE]
14.

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

ROCKET AF Study Investigators.

Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.

PMID:
20211293
[PubMed - indexed for MEDLINE]
15.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

PMID:
22787066
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001938. Review.

PMID:
17636690
[PubMed - indexed for MEDLINE]
17.

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2001;(1):CD001938. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001938.

PMID:
11279741
[PubMed - indexed for MEDLINE]
19.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
[PubMed - indexed for MEDLINE]
20.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk